HW
PMD

Hancock Whitney’s Psychemedics Corporation PMD Stock Holding History

Hancock Whitney’s Portfolio PMD Stock Details PMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-13,505
Closed -$288K – 611
2018
Q1 		$288K Buy
+13,505
New +$280K 0.01% 489

Other funds holding PMD

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
CIC
Crawford Investment Counsel Atlanta, Georgia $5.85B AUM 12.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
NSIM
North Star Investment Management Chicago, Illinois $1.65B AUM 20.56% 1-Year Est. Return

Hancock Whitney's PMD Position: Q2 2018 in Review

Hancock Whitney sold out of Psychemedics Corporation (PMD) in Q2 2018, closing a stake of 13,505 shares — an estimated $288K sold.

Hancock Whitney first reported a position in PMD in Q1 2018 and held it in 1 quarter. The position peaked at $288K in Q1 2018. 51 funds tracked by Wall St. Rank hold PMD as of Q2 2018.

  • Hancock Whitney reported no remaining Psychemedics Corporation position as of Q2 2018 after selling out during the quarter.
  • Hancock Whitney sold 13,505 Psychemedics Corporation shares in Q2 2018, an estimated $288K.
  • Hancock Whitney first reported a position in Psychemedics Corporation in Q1 2018 and held it in 1 quarter.
  • Hancock Whitney's Psychemedics Corporation position peaked at $288K in Q1 2018.
  • 51 funds tracked by Wall St. Rank held Psychemedics Corporation as of Q2 2018.

Based on Hancock Whitney's 13F filing for Q2 2018, filed 14 Aug 2018.